Polymyositis: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}}; | {{CMG}}; {{AE}} {{CZ}} | ||
{{ | {{SK}} Wagner-Unverricht syndrome; dermatomyositis; idiopathic inflammatory myopathy; myositis, multiple; polymyositis ossificans; polymyositis, idiopathic | ||
==Overview== | ==Overview== | ||
'''Polymyositis''' is a type of [[inflammation|inflammatory]] [[myopathy]], related to [[dermatomyositis]] and [[inclusion body myositis]]. Polymyositis means 'many muscle inflammation'. | '''Polymyositis''' is a type of [[inflammation|inflammatory]] [[myopathy]], related to [[dermatomyositis]] and [[inclusion body myositis]]. Polymyositis means 'many muscle inflammation'. | ||
| Line 27: | Line 14: | ||
Polymyositis, like dermatomyositis, strikes females with greater frequency than males. The skin involvement of dermatomyositis is absent in polymyositis. | Polymyositis, like dermatomyositis, strikes females with greater frequency than males. The skin involvement of dermatomyositis is absent in polymyositis. | ||
===Causes | ==Historical Perspective== | ||
==Classification== | |||
==Pathophysiology== | |||
==Causes== | |||
===Drug Side Effect=== | ===Drug Side Effect=== | ||
| Line 35: | Line 28: | ||
* [[Penicillamine]] | * [[Penicillamine]] | ||
==Prognosis== | ==Differentiating Polymyositis from other Diseases== | ||
Sporadic [[inclusion body myositis]] (sIBM): IBM is often confused with (misdiagnosed as) polymyositis and polymyositis that does not respond to treatment is likely IBM. sIBM comes on over months to years, polymyositis comes on over weeks to months. It appears that sIBM and polymyositis share some common features, especially the initial sequence of immune system activation, however, polymyositis does not display the subsequent muscle degeneration and protein abnormalities as seen in IBM. As well, polymyositis tends to respond well to treatments, IBM does not. IBM and polymyositis apparently involve different disease mechanisms than are seen in [[dermatomyositis]]. | |||
==Epidemiology and Demographics== | |||
===Age=== | |||
===Gender=== | |||
===Race=== | |||
==Risk Factors== | |||
==Natural History, Complications and Prognosis== | |||
The prognosis for polymyositis varies. Most people respond fairly well to therapy, but some have a more severe disease that does not respond adequately to therapies and are left with significant disability. | The prognosis for polymyositis varies. Most people respond fairly well to therapy, but some have a more severe disease that does not respond adequately to therapies and are left with significant disability. | ||
| Line 42: | Line 45: | ||
==Diagnosis== | ==Diagnosis== | ||
[[Diagnosis]] is fourfold, including elevation of [[creatine kinase]], [[sign (medicine)|signs]] and [[symptom]]s, electromyograph (EMG) alteration, and a positive muscle [[biopsy]] | ===Diagnostic Criteria=== | ||
[[Diagnosis]] is fourfold, including elevation of [[creatine kinase]], [[sign (medicine)|signs]] and [[symptom]]s, electromyograph (EMG) alteration, and a positive muscle [[biopsy]]. | |||
===Symptoms=== | |||
===Physical Examination=== | |||
===Laboratory Findings=== | |||
===Imaging Findings=== | |||
===Other Diagnostic Studies=== | |||
==Treatment== | ==Treatment== | ||
There is no cure for polymyositis, but the symptoms can be treated. Options include medication, physical therapy, exercise, heat therapy (including microwave and ultrasound), orthotics and assisted devices, and rest. | |||
===Medical Therapy=== | |||
Treatment generally involves [[glucocorticoids]], especially [[prednisone]]. At present, a number of studies are underway to determine whether patients diagnosed with polymyositis will benefit from newer drugs inhibiting the biologic effects of TNF alpha, such as Infliximab ("Remicade"). | |||
The standard treatment for polymyositis is a corticosteroid drug, given either in pill form or intravenously. Immunosuppressant drugs, such as [[azathioprine]] and [[methotrexate]], may reduce inflammation in people who do not respond well to [[prednisone]]. | The standard treatment for polymyositis is a corticosteroid drug, given either in pill form or intravenously. Immunosuppressant drugs, such as [[azathioprine]] and [[methotrexate]], may reduce inflammation in people who do not respond well to [[prednisone]]. | ||
| Line 55: | Line 69: | ||
Other immunosuppressive agents used to treat the inflammation associated with polymyositis include [[cyclosporine A]], [[cyclophosphamide]], and [[tacrolimus]]. | Other immunosuppressive agents used to treat the inflammation associated with polymyositis include [[cyclosporine A]], [[cyclophosphamide]], and [[tacrolimus]]. | ||
===Surgery=== | |||
===Prevention=== | |||
Physical therapy is usually recommended to prevent [[muscle atrophy]] and to regain muscle strength and range of motion. | Physical therapy is usually recommended to prevent [[muscle atrophy]] and to regain muscle strength and range of motion. | ||
Revision as of 19:48, 30 June 2016
|
WikiDoc Resources for Polymyositis |
|
Articles |
|---|
|
Most recent articles on Polymyositis Most cited articles on Polymyositis |
|
Media |
|
Powerpoint slides on Polymyositis |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Polymyositis at Clinical Trials.gov Clinical Trials on Polymyositis at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Polymyositis
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Polymyositis Discussion groups on Polymyositis Patient Handouts on Polymyositis Directions to Hospitals Treating Polymyositis Risk calculators and risk factors for Polymyositis
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Polymyositis |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Synonyms and keywords: Wagner-Unverricht syndrome; dermatomyositis; idiopathic inflammatory myopathy; myositis, multiple; polymyositis ossificans; polymyositis, idiopathic
Overview
Polymyositis is a type of inflammatory myopathy, related to dermatomyositis and inclusion body myositis. Polymyositis means 'many muscle inflammation'.
Polymyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness. Polymyositis affects skeletal muscles (those involved with making movement) on both sides of the body. It is rarely seen in persons under age 18; most cases are in adults between the ages of 31 and 60. Slow, but progressive muscle weakness starts in the proximal muscles (muscles closest to the trunk of the body) which eventually leads to difficulties climbing stairs, rising from a sitting position, lifting objects, or reaching overhead. People with polymyositis may also experience arthritis, shortness of breath, difficulty swallowing and speaking, and heart arrhythmias. In some cases of polymyositis, distal muscles (muscles further away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses. Polymyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus. Polymyositis may also be associated with infectious disorders, such as HIV-AIDS.
Polymyositis tends to become evident in adulthood, presenting with bilateral proximal muscle weakness, often noted in the upper legs due to early fatigue while walking. Sometimes the weakness presents itself by the person being unable to rise from a seated position without help, or inability to raise their arms above their head. The weakness is generally progressive, accompanied by lymphocytic inflammation (mainly cytotoxic T8 lymphocytes). The cause is unknown, but seems to be related to autoimmune factors, genetics, and perhaps viruses. In rare cases, the cause is known to be infectious, associated with the pathogens that cause Lyme disease, toxoplasmosis, and others.[1]
Polymyositis, like dermatomyositis, strikes females with greater frequency than males. The skin involvement of dermatomyositis is absent in polymyositis.
Historical Perspective
Classification
Pathophysiology
Causes
Drug Side Effect
Differentiating Polymyositis from other Diseases
Sporadic inclusion body myositis (sIBM): IBM is often confused with (misdiagnosed as) polymyositis and polymyositis that does not respond to treatment is likely IBM. sIBM comes on over months to years, polymyositis comes on over weeks to months. It appears that sIBM and polymyositis share some common features, especially the initial sequence of immune system activation, however, polymyositis does not display the subsequent muscle degeneration and protein abnormalities as seen in IBM. As well, polymyositis tends to respond well to treatments, IBM does not. IBM and polymyositis apparently involve different disease mechanisms than are seen in dermatomyositis.
Epidemiology and Demographics
Age
Gender
Race
Risk Factors
Natural History, Complications and Prognosis
The prognosis for polymyositis varies. Most people respond fairly well to therapy, but some have a more severe disease that does not respond adequately to therapies and are left with significant disability.
In rare cases individuals with severe and progressive muscle weakness will develop respiratory failure or pneumonia. Difficulty swallowing may cause weight loss and malnutrition.
Diagnosis
Diagnostic Criteria
Diagnosis is fourfold, including elevation of creatine kinase, signs and symptoms, electromyograph (EMG) alteration, and a positive muscle biopsy.
Symptoms
Physical Examination
Laboratory Findings
Imaging Findings
Other Diagnostic Studies
Treatment
There is no cure for polymyositis, but the symptoms can be treated. Options include medication, physical therapy, exercise, heat therapy (including microwave and ultrasound), orthotics and assisted devices, and rest.
Medical Therapy
Treatment generally involves glucocorticoids, especially prednisone. At present, a number of studies are underway to determine whether patients diagnosed with polymyositis will benefit from newer drugs inhibiting the biologic effects of TNF alpha, such as Infliximab ("Remicade").
The standard treatment for polymyositis is a corticosteroid drug, given either in pill form or intravenously. Immunosuppressant drugs, such as azathioprine and methotrexate, may reduce inflammation in people who do not respond well to prednisone.
Periodic treatment using intravenous immunoglobulin can also improve recovery.
Other immunosuppressive agents used to treat the inflammation associated with polymyositis include cyclosporine A, cyclophosphamide, and tacrolimus.
Surgery
Prevention
Physical therapy is usually recommended to prevent muscle atrophy and to regain muscle strength and range of motion.
References
- ↑ Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2005. ISBN 0-07-139140-1
Template:Diseases of the musculoskeletal system and connective tissue
de:Polymyositis ku:Polîmiyozît he:פולימיוזיטיס fi:Polymyosiitti